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Abstract 
 
 
Death Receptor 5 (DR5) is a pro-apoptotic cell-surface receptor that is a potential therapeutic 
target in cancer. Despite the potency of DR5-targeting agents in pre-clinical models, the 
translation of these effects into the clinic remains disappointing. Herein, we report an 
alternative approach to exploiting DR5 tumor expression using antibody-targeted, 
chemotherapy-loaded nanoparticles. We describe the development of an optimized polymer-
based nanotherapeutic incorporating both a functionalized polyethylene glycol (PEG) layer 
and targeting antibodies to limit premature phagocytic clearance whilst enabling targeting of 
DR5-expressing tumor cells. Using the HCT116 colorectal cancer model, we show that 
following binding to DR5, the nanoparticles activate caspase 8, enhancing the anti-tumor 
activity of the camptothecin payload both in vitro and in vivo. Importantly, the combination 
of nanoparticle-induced DR5 clustering with camptothecin delivery overcomes resistance to 
DR5-induced apoptosis caused by loss of BAX or overexpression of anti-apoptotic FLIP. 
This novel approach may improve the clinical activity of DR5-targeted therapeutics while 
increasing tumor-specific delivery of systemically toxic chemotherapeutics. 
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Introduction 
 
 
DR5 is a type I transmembrane protein belonging to the Tumor Necrosis Factor Receptor 
(TNFR) family. DR5, like other TNFRs, pre-assembles as receptor oligomers within the cell 
membrane via a pre-ligand assembly domain 1. Binding of its cognate trimeric ligand, TNF-
related apoptosis-inducing ligand (TRAIL) induces higher order clustering of DR5 that 
triggers the recruitment of the adaptor molecule Fas-associated death domain and procaspase 
8 to the cytoplasmic death domain of the receptor 2, 3. The formation of this Death-Inducing 
Signaling Complex (DISC) results in homo-dimerization and activation of caspase 8, which 
can directly activate downstream caspases in “type I” cells or cleave the Bcl-2 family 
member BID, resulting in activation of BAX and induction of mitochondrial-dependent 
apoptosis in “type II” cells 4.  
 
 
DR5 has been proposed as a therapeutic target in various solid cancers 5, and we have 
previously reported that patients with stage II and stage III colorectal tumors express 
significantly higher levels of DR5 compared to normal colon tissue; however, colorectal 
tumors also overexpress the endogenous caspase 8 inhibitor FLIP, a major mediator of 
resistance to DR5-induced apoptosis 6. DR5-specific agonistic antibodies such as 
conatumumab have been developed to target diseases such as metastatic colorectal cancer 7, 8, 
and promising effects in preclinical studies as a single agent and in combination with various 
chemotherapies including the topoisomerase I inhibitor irinotecan have been observed 5, 9. 
However to date, conatumumab and other DR5 agonists have failed to demonstrate 
convincing efficacy in clinical trials. This is thought to be a consequence of weak DR5 
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activation through insufficient receptor clustering in patients and/or intrinsic resistance to 
death receptor-initiated apoptosis 7, 8, 10. 
 
 
Previously, we have shown in vitro that the conjugation of agonistic antibodies targeting 
TNFR family members on the surface of polymeric nanoparticles (NP) results in enhanced 
avidity and potently induces receptor activation 11, 12.  In an effort to overcome some of the 
current issues with targeting DR5 using antibody-based therapies, we have examined their 
potential in a novel antibody-conjugate platform. Here, we describe the development and 
evaluation of DR5-targeted and camptothecin (CPT)-loaded poly(lactic-co-glycolic) acid 
(PLGA) NPs optimized for in vivo application. The NPs were engineered to include both a 
“stealth” hydrophilic PEG corona to minimize phagocytosis in addition to DR5-specific 
antibodies to target tumor cells and induce apoptosis. We demonstrate the pro-apoptotic 
effects of the platform in vivo using HCT116 adenocarcinoma xenografts and reveal that this 
novel nanomedicine has the potential to overcome frequent DR5 resistance mechanisms in 
colorectal cancer, namely loss of BAX expression and overexpression of FLIP. 
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Results 
 
 
Synthesis and characterization of antibody-targeted PEGylated PLGA NPs 
 
 
Uniform NP populations were prepared using single emulsion evaporation with COOH-
PEG3400-PLGA copolymer at 25% (w/w) blended with PLGA RG502H (Fig. 1a and Table 
1). The exposed carboxyl groups on the surface deriving from the functionalized copolymer 
allowed subsequent conjugation of the DR5-specific antibody conatumumab via free amino 
groups within the antibody chain, using carbodiimide chemistry (16.6 ± 4.2 µg per mg NP). 
Furthermore, the presence of the PEG corona significantly inhibited phagocytosis by murine 
macrophages (Fig. 1b). For drug-loaded NP preparations, CPT was mixed with the polymer 
in the organic phase before emulsification. As observed previously, the inclusion of CPT in 
the formulation increased the size and heterogeneity of the NP population 12. Similarly, 
increases of NP size distribution were obtained for DR5-NPs due to the conjugation of high 
molecular weight antibodies to the NP surface (Table 1). Further confirmation of the size 
distribution (~200 nm) of blank and CPT-loaded DR5-NPs was obtained by scanning electron 
microscopy (SEM) (Fig. 1c). Finally, the controlled release profile of the drug from the 
particles was monitored in PBS containing 50% serum at 37 °C, where a cumulative release 
of the compound was observed over a period of 6 days (Fig. 1d). 
 
 
 6 
DR5-NPs initiate apoptosis  
 
 
The ability of the DR5-NPs to bind to colon adenocarcinoma HCT116 cells was next 
examined. Confocal microscopy using NPs formulated with a fluorescently labeled PLGA 
firstly revealed that DR5 targeting enhanced the binding of the NPs to the cells. DR5 co-
staining revealed broad distribution of DR5 throughout the cells and some co-localization 
with DR5-NPs, which was not evident with nude NPs; indicating that the antibody-
conjugated NPs could bind to DR5 on the cells (Fig. 2a). To confirm this interaction more 
conclusively, Western blot analysis of the protein complexes interacting with the NPs was 
performed. This showed that the DR5-NPs (but not the nude or IgG control NPs) were bound 
to DR5 in a complex with caspase 8 (Fig. 2b). Caspase 8 was present in this complex 
predominantly in its cleaved p41/43-forms, but also in its p18-form indicative of its 
dimerization and activation at the DR5 DISC. Fully processed p18-caspase 8 can remain 
bound at the DISC or be released into the cytoplasm 13, explaining its presence in both the 
supernatant and precipitated fraction. In agreement with the observed recruitment and 
processing of procaspase 8, enzymatic activity assays confirmed significantly increased 
levels of both caspase 8 and executioner caspases 3/7 following treatment with DR5-NPs 
(Fig. 2c). Control NPs and free anti-DR5 antibody were incapable of inducing this effect. The 
enhanced receptor activation induced by DR5-NPs over free antibody is the consequence of 
the simultaneous presentation of multiple binding paratopes on the NP surface that efficiently 
induces DR5 clustering and DISC formation. Furthermore, in a competition assay, caspase 8 
activity was significantly reduced when the cells were pre-incubated with excess free DR5-
specific antibody (Fig. S1a), further highlighting the specificity of this interaction.  
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The impact of NP-mediated DR5 clustering on cell viability was next assessed using MTT 
assays, which revealed that DR5-NPs induce a more pronounced cytotoxic effect than free 
antibody (Fig. 2d). Moreover, colony formation was clearly reduced after only 1 h of 
incubation with DR5-NPs, whereas free antibody did not impact on clonogenic survival (Fig. 
2e). The observed pro-apoptotic effect was DR5-dependent as shown by receptor silencing 
using siRNA (Fig. S1b and c). Furthermore, normal colon fibroblasts (CCD-18Co), which 
express low levels of DR5, are significantly less sensitive to DR5-NPs than HCT116 tumor 
cells (Fig. S2). Finally, we assessed the stability of the DR5-NPs following incubation in 
50% serum at 37 °C. This demonstrated that the antibody remained on the NP surface up to 
96 h (Fig. 2f) and that within this timeframe, the NPs maintained their ability to significantly 
activate caspase 8 (Fig. 2g). 
 
 
CPT loading enhances apoptosis induced by DR5-NPs 
 
 
Next, we investigated the potential of exploiting this targeted NP formulation as a carrier for 
the chemotherapeutic drug CPT. Incubation with CPT-loaded NPs caused S- and G2/M-arrest 
within 24 h indicative of CPT-induced DNA damage (Fig. 3a). Furthermore, it was shown 
that CPT loading induced Thr68-phosphorylation of Chk2 (pThr68-Chk2) (Fig. 3b); Chk2 is 
an upstream kinase activated by ATM in response to DNA double-strand breaks such as those 
caused by topoisomerase-I inhibition 14, 15. Apoptotic cell death was detected by flow 
cytometry in 40% of the cells 24 h after treatment with DR5-NPs, and this was enhanced to 
70% when CPT was loaded into the NP core (Fig. 3c). This effect increased to 80% by 48 h, 
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with the vast majority exhibiting a late stage apoptotic phenotype. Notably, the extent of 
apoptosis induced by the blank DR5-NPs did not increase between 24 and 48 h, further 
highlighting the additional effects that were induced by encapsulated CPT. The effects of 
CPT DR5-NPs were also investigated in other colorectal cancer cell lines. The LoVo 
metastatic colorectal cancer cell line is highly sensitive to DR5-NP-mediated cell death and 
CPT does not further enhance this effect, whereas the TRAIL-resistant RKO and HT29 cell 
lines 16 were markedly sensitized to DR5-mediated cell death through the co-delivery of CPT 
(Fig. 3d). Blank NPs had no effect on cell viability at the applied polymer concentrations 
(Fig. S3). 
 
 
DR5-targeting potentiates the anti-tumor effects of CPT  
 
 
The therapeutic effects of DR5-NPs were next evaluated in vivo using athymic mice bearing 
HCT116 xenografts. The tumor volume was reduced by ~35% in mice treated with DR5-NPs 
over both PBS and control-IgG conjugated NPs by day 22 following five serial treatments. 
These effects were comparable to the freely administered anti-DR5 antibody without 
significant weight loss during the time of treatment (Fig. 4a and b). The effectiveness of the 
antibody, free or NP-bound, was clearly evident through immunohistochemical staining of 
cleaved caspase 3, highlighting the ability of the antibody to initiate apoptosis in both these 
treatment groups (Fig. 4c). It has recently been shown that free DR5-targeted antibodies are 
cross-linked through Fcγ receptors (FcγR) that are found on a range of immune cells 17-19 and 
therefore, it was not unexpected that free anti-DR5 antibodies exhibited activity in murine 
tumor models. The therapeutic effects generated by inclusion of CPT in the NP formulations 
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were also assessed. At the study end point, tumor growth was significantly inhibited by 65% 
following serial administration of CPT nude NPs, and this anti-tumor activity was further 
enhanced when the NPs were coated with DR5-targeting antibodies inhibiting tumor growth 
by 74% (Fig. 4a). To determine whether NP-delivered CPT induced DNA damage, the tumor 
lysates were analyzed for pThr68-Chk2. Significant increases in pThr68-Chk2 were observed 
in tumors from animals treated with CPT nude NPs and CPT DR5-NPs compared to tumors 
from blank IgG-NP treated mice (Fig. 4d). Collectively, these results demonstrate that both 
active pharmaceutical ingredients of the nanoconjugate have produced therapeutic effects in 
vivo and that the combination of CPT encapsulated in DR5-NPs yields superior anti-tumor 
activity.  
 
 
DR5-NPs overcome BAX deficiency in combination with CPT 
 
 
Intrinsic resistance of tumors toward DR5-mediated apoptosis may be the major factor 
limiting the clinical utility of DR5-targeting agonists and explain the relatively disappointing 
results of the clinical trials of these agents that have been reported to date 10. Loss of BAX 
expression is frequently observed in microsatellite unstable colorectal cancer 20, and we have 
previously reported that BAX null HCT116 cells are resistant to TRAIL-induced apoptosis 21. 
Hence, we examined the potential of CPT DR5-NPs to overcome apoptosis resistance in 
BAX null HCT116 cells 22. As HCT116 are type II cells 21, DR5-mediated apoptosis is 
dependent on amplification of caspase activity via the intrinsic mitochondria-regulated 
apoptotic pathway, and as anticipated, the absence of BAX rendered these cells insensitive to 
DR5-NPs, as shown by the lack of cleaved PARP (lane 7, Fig. 5a). Initial treatments of these 
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cells with CPT DR5-NPs in vitro produced no therapeutic effect, but a pre-incubation with a 
sub-lethal concentration of free CPT was found to sensitize the BAX null cells to DR5 
agonism, as indicated by PARP cleavage (lane 8, Fig. 5a). Interestingly, we observed that 
these effects were concomitant with a reduction in the levels of the anti-apoptotic caspase 
inhibitor XIAP 23. Birinapant is a small molecule that antagonizes inhibitors of apoptosis 
(IAPs) including XIAP 24, and the pre-treatment with this small molecule inhibitor sensitized 
the resistant BAX null cells to DR5-NP-mediated apoptosis (Fig. 5b); similar effects were 
observed using an XIAP-targeted siRNA (Fig. S4). The effects caused by birinapant were not 
as dramatic as observed following pre-treatment with CPT (Fig. S5), suggesting that other 
molecular events favoring cell death are induced by CPT, such as upregulation of DR5 cell 
surface expression, which was detected following CPT treatment (Fig. S6).  
 
 
On the basis of these findings, a sequential treatment strategy was designed for treating Bax 
null cells with CPT DR5-NPs (and associated controls) as outlined in Fig. 5c. Induction of 
cell cycle arrest and onset of apoptosis in the cells was examined by flow cytometry. 
Following the initial 24 h treatment with CPT loaded NPs, cell cycle arrest in S- and G2/M-
phases was apparent, but none of the treatment groups induced cell death as indicated by a 
lack of cells in the sub-G1 phase (Fig. 5c, 24 h). The CPT-induced G2/M-arrest was more 
pronounced after subsequent incubation in fresh medium for a further 24 h and a small cell 
population (~4%) underwent cell death (Fig. 5c, 48 h). However, after re-treatment for only 6 
h, the CPT DR5-NPs induced a significant increase in cell death, whereas the other NP 
treatment groups were unable to induce significant effects compared to cells treated with 
blank nude NPs (Fig. 5c, 54 h). This corresponded with significantly increased activation of 
caspase 8 and caspases 3/7 (Fig. 5d), and PARP cleavage (Fig. 5e). Further protein analysis 
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also revealed that DR5 was upregulated 24 h following treatment with CPT loaded NPs, and 
this effect was enhanced after 48 h, the point of re-treatment. At this time-point, and 
consistent with earlier results (Fig. 5a), XIAP was downregulated in cells treated with CPT 
loaded NPs. Upon re-treatment of the cells with the CPT DR5-NPs, DR5 expression was 
decreased (Fig. 5e); this is most likely due to receptor internalization and lysosomal 
degradation as proposed by Austin et al. 25. We also analysed levels of BAK, which functions 
similarly to BAX by forming pores in the outer mitochondrial membrane during apoptosis 26. 
Small alterations in BAK levels were observed but these did not correlate with the enhanced 
induction of apoptosis with CPT DR5-NPs. Taken together, these results demonstrate that 
repeated treatments with CPT DR5-NPs are able to overcome apoptotic resistance in 
colorectal cancer cells caused by the absence of BAX through downregulation of XIAP and 
simultaneous upregulation of DR5. 
 
 
DR5-NPs overcome apoptosis resistance mediated by FLIP  
 
 
Another major resistance mechanism to DR5-initiated apoptosis is upregulation of FLIP, 
which is an endogenous inhibitor of caspase 8 and can cause resistance to DR5-mediated 
apoptosis 27. FLIP is found overexpressed in tissues of a range of malignancies including 
colorectal carcinoma 6, 28, 29. Firstly, we examined the impact of CPT treatment on 
endogenous FLIP proteins in wild-type HCT116 cells. Treatment with a concentration of 
CPT (1 µM) that induced PARP cleavage within 24 h markedly downregulated FLIP long 
(FLIPL) levels (Fig. 6a). This effect was accompanied by increasing activity of caspase 8 
with ascending CPT concentrations, which reached significance at the highest CPT 
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concentration (Fig. 6b). As no decrease in FLIP mRNA levels were observed in cells treated 
with 1 µM CPT for 24 h (Fig. S7), these results suggest that FLIP is degraded following 
treatment with this concentration of CPT, resulting in activation of caspase 8. To investigate 
the effect of FLIP overexpression on DR5-NP-induced apoptosis and the potential to 
overcome this resistance mechanism by co-delivery of CPT, we investigated HCT116 cells 
that overexpress the two main FLIP splice isoforms; FLIPL and FLIP short (FLIPS). Similar 
to the observations with endogenous protein, both exogenous splice variants were 
downregulated following CPT treatment, and this correlated with PARP cleavage (Fig. 6c). 
Notably, overexpression of FLIPL did not impact on the ability of DR5-NPs to induce 
apoptosis following treatment with DR5-NPs (Fig. 6d). In contrast, FLIPS overexpression 
reduced apoptosis, however, the impact of FLIPS overexpression was significantly less when 
CPT was encapsulated into DR5-NPs; this reflects the downregulation of exogenous FLIPS in 
response to treatment with both CPT-loaded NP formulations (Fig. 6e). The differential 
effects observed in the two FLIP overexpressing cell lines are most likely due to the different 
expression levels of the two exogenous FLIP proteins with FLIPS overexpressed ~4 times 
more highly (Fig. 6c), and reflected by the observation that FLIPS overexpression was very 
effective at blocking apoptosis induced by co-treatment with recombinant human TRAIL 
(rhTRAIL) and CPT (Fig. S8). These results demonstrate that DR5-NPs can activate the 
extrinsic apoptotic pathway despite moderate (FLIPL model) and high (FLIPS model) 
overexpression of FLIP, and this effect is further enhanced by co-delivery of CPT. 
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Discussion 
 
In this current work, we have developed a polymeric NP drug delivery system suitable for in 
vivo application that incorporates an antibody therapeutic targeting DR5 and chemotherapy 
payload. The therapeutic effectiveness of this modality was validated in vivo, and moreover, 
we showed that common resistance mechanisms to DR5-initiated apoptosis could be 
overcome by this approach.  
 
 
We have previously examined the conjugation of antibodies to the surface of PLGA-based 
NPs to elicit improved uptake in tumor cell populations in vitro 11, 12. PLGA is a 
biodegradable and biocompatible polymer approved in various medical applications 30. 
However, these polymeric NPs are hydrophobic and once in circulation, serum proteins can 
rapidly aggregate on the surface of such hydrophobic nanomaterials promoting macrophage 
uptake 31. The inclusion of a surface layer of hydrophilic polymers such as PEG can 
counteract macrophage uptake and reduce the rapid NP clearance that occurs in the organs of 
the mononuclear phagocyte system 32.  This has been shown to therefore enhance the half-life 
of PEGylated PLGA-based NPs 33,34. Here, we successfully incorporated a carboxyl-
functionalized PEG3400 into the formulation and, in agreement with previous studies, found 
that macrophage uptake of the NPs was diminished.    
 
 
The conjugation of a DR5-targeting antibody to the surface of these NPs was shown to 
promote binding to the target receptor and induce formation of the apoptosis-inducing DR5 
DISC. Although the presentation of the DR5 antibody on the surface of the NP significantly 
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increased apoptosis compared to free antibody in vitro, this differential effect was not evident 
in vivo. It is well characterized that the free anti-DR5 antibody with only two paratopes is 
inefficient at promoting higher-order clustering and activation of DR5 in cell-based assays 9. 
However, once applied in murine in vivo studies, it does achieve agonistic activity 
comparable to DR5-NPs. This phenomenon is dependent on FcγR engagement of the 
antibody on myeloid cells which facilitates multiple paratope presentation that in turn drives 
receptor activation on the surface of the tumor cells 17-19. The clinical significance of this 
effect in patients remains poorly characterized, and FcγR polymorphisms affecting antibody 
affinity may dictate the effectiveness of the drug 8, 35. However, this issue is circumvented by 
our novel approach of using NPs to present multiple paratopes to drive DR5 activation on the 
surface of tumor cells.  
 
 
Considering the physiological role of TRAIL/DR5 in tumor immune surveillance 36, it is not 
surprising that many cancer cells develop resistance mechanisms in order to escape 
destruction mediated by TRAIL-expressing immune cells 10. We hypothesized that efficient 
receptor crosslinking through DR5-NPs, in combination with the delivery of a cytotoxic 
agent, may enhance DR5-mediated apoptosis and more importantly help to overcome 
frequently occurring resistance mechanisms in cancer cells. CPT was selected as the cargo 
chemotherapy in this approach but issues with its solubility, stability and toxicity profile have 
led to the development and clinical application of derivatives, namely irinotecan and 
topotecan 37. However, the promising clinical results of CRLX101, a polymeric nano-
formulation of CPT currently investigated in clinical phase II trials, clearly highlight the 
therapeutic potential of this highly potent compound when delivered appropriately 38. CPT 
NPs exhibited significant anti-tumor effects in HCT116 xenografts that were markedly 
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enhanced when the NPs were functionalized with DR5 antibody; this is consistent with the 
results of combination studies of conatumumab with irinotecan in vitro and in vivo 9.  The 
HCT116 tumors proved highly sensitive to the levels of CPT encapsulated in the NPs, and 
this may have partially masked the therapeutic advantage of the conjugated DR5 antibodies. 
Nonetheless, the results obtained from the DR5-targeted NP groups clearly show that the 
conjugates were able to localize to the tumor and initiate apoptosis. Given that this antibody 
does not cross-react with murine DR5, future studies will require a species-matched agonistic 
antibody in order to undertake detailed biodistribution and pharmacokinetic analyses; 
examining parameters such as particle size, antibody orientation and use of antibody 
fragments to optimize the pro-apoptotic effects and evaluate the ability of the antibodies to 
enhance targeting of the NP to tumors. 
 
 
Another key consideration in resistance of tumors to extrinsic apoptosis is the requirement for 
mitochondrial amplification of an extrinsic apoptotic signal, which determines whether cells 
are classified as type I (not required) and type II cells (required) 10. The deregulation of 
proteins within the mitochondrial pathway through overexpression of anti-apoptotic Bcl-2 39 
and Bcl-XL 40 or loss of BAX protein 22, which commonly occur in human malignancies 41, 
renders type II cells resistant to extrinsic apoptosis. Therefore, we investigated whether CPT-
loaded DR5-NPs could overcome the resistance of BAX-deficient type II HCT116 cells to 
DR5-mediated apoptosis. Pre-treatment with CPT-loaded NPs increased DR5 expression in 
the BAX-deficient cells and also caused a marked downregulation of XIAP. XIAP is the only 
IAP that directly inhibits caspases, binding with high affinity to effector caspases 3/7 and 
initiator caspase 9, and is recognized as a critical inhibitor of death receptor-induced 
apoptosis 42. Importantly, serial treatments with CPT-loaded, but not blank DR5-NPs, 
 16 
overcame resistance to TRAIL-induced apoptosis in BAX null cells. Mechanistically, this is 
most likely a result of simultaneous upregulation of DR5 and downregulation of XIAP. This 
is in agreement with previous work showing that chemo-sensitization of BAX null HCT116 
cells to TRAIL-mediated apoptosis was a consequence of p53-mediated upregulation of DR5 
43 and our own work showing that resistance of BAX null cells to TRAIL-induced apoptosis 
can be overcome by downregulating XIAP 21.  
 
 
FLIP is a key regulator of death receptor-mediated apoptosis and is found overexpressed in a 
range of malignancies 6, 28, 29, 44. High expression of FLIP is proposed to contribute to 
resistance to death receptor-targeted therapy by disrupting procaspase 8 homo-dimerization 
and activation at the DISC 10, 27. The results presented herein indicate that the enhanced 
receptor oligomerization induced by DR5-NPs can overcome FLIP-mediated resistance to 
DR5-induced apoptosis when FLIP is overexpressed at moderate levels (FLIPL model). 
Moreover, even in cells with high levels of FLIP expression (FLIPS model), DR5-NPs 
induced high levels of apoptosis, and these cells could be further sensitized through 
incorporation of CPT into the NP core, as co-delivery of CPT resulted in FLIP 
downregulation. Taken together, these results highlight the potential of this DR5-targeted 
platform to overcome these resistance mechanisms. 
 
 
Given the recent advances in clinical application of polymer-based nanotherapeutics 38, 45, 46 
and promising results with antibody drug conjugates (ADCs) such as Trastuzumab emtansine 
(T-DM1) 47, therapies that bring together anti-cancer drugs in a single therapeutic entity 
represent exciting new approaches for the treatment of cancer. In this study we have 
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demonstrated the therapeutic potential of using drug-loaded, tumor-targeted NPs as an 
alternative ADC strategy. 
 
 
Materials and Methods 
 
 
NP synthesis 
 
 
NPs were prepared by single emulsion evaporation with 25% (w/w) of COOH-PEG-PLGA 
copolymer (see Supplementary Material and Methods for polymer synthesis) mixed with 
PLGA RG502H (Evonik Industries, Germany). The polymer (20 mg) was dissolved in 1 mL 
of dichloromethane and injected into the aqueous phase (7 mL) containing 2.5% (w/v) 
polyvinyl alcohol in MES buffer (50 mM, pH 5.0) to provide optimal conditions for 
downstream antibody conjugation. Emulsification was achieved by pulsary sonication on ice 
for 90 s and the resulting emulsion was stirred overnight to allow the organic solvent to 
evaporate. Fluorescently labeled NPs were generated by addition of 0.1% (w/w) rhodamine 
6G (Sigma-Aldrich, UK) into the organic phase for macrophage uptake studies or by use of 
rhodamine B-conjugated PLGA (AV11, Akina Inc, West Lafayette, IN) for confocal 
microscopy. (S)-(+)-CPT (Sigma-Aldrich, UK) NPs were generated by the addition of the 
drug into the organic phase whereas the amount varied depending on the application (0.50% 
or 3.33% (w/w) for in vitro or in vivo respectively). The NPs were purified in MES buffer by 
3 wash-spin cycles and conatumumab (provided by Amgen) was attached similarly to a 
method described previously 11, 12. Free carboxyl groups on the NP surface were activated in 
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MES buffer with 2 mM 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) and 14 mM 
N-Hydroxysuccinimide (NHS) for 20 min, centrifuged at 20 000 g and conatumumab or 
control human IgG (Life Technologies, UK; 50 µg per mg of polymer) was incubated for 1 h 
under stirring. NPs were washed once in PBS for removal of unbound antibody. The 
characterization of the nanoparticles is described in the Supplementary Material and 
Methods. 
 
 
Cell culture 
 
 
The HCT116 wild-type and Bax-/- mutant cell lines were kindly provided by Professor Bert 
Vogelstein (Johns Hopkins University) and cultured in McCoy 5A medium supplemented 
with 10% FBS. HCT116 cell lines overexpressing FLIPS and FLIPL were generated as 
described previously 48. The Raw 264.7, RKO and HT-29 cells were obtained from ATCC, 
LoVo cells from ECACC and maintained in supplemented DMEM.  
 
 
NP uptake analysis 
 
 
Raw 264.7 cells were incubated with 0.1 mg/mL of rhodamine 6G-loaded NPs for 1 h and 
washed with PBS (2x), stripping buffer (50 mM glycine, 150 mM NaCl, pH3) and PBS (1x) 
before PE fluorescence was analyzed by flow cytometry. For confocal microscopy, the cells 
were incubated with rhodamine B-labeled NPs (0.2 mg/mL) for 1 h and then washed in PBS 
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(3x), stripping buffer (1x) and PBS (3x). The cells were fixed using 4% paraformaldehyde 
followed by further washing steps in PBS (3x). DR5 was stained using anti-DR5 antibody 
(1:200, Cell Signaling Technologies, Danvers, MA) and Alexa Fluor 488 donkey anti-rabbit 
antibody (1:200, Life Technologies, UK). The cover slips were sealed with Prolong Gold 
Antifade reagent containing DAPI (Life Technologies, UK) and the cells imaged using the 
Leica SP5 Confocal Microscope (x 63 lens zoomed x 1-4 with a 1024x1024 frame and 400Hz 
scanning speed). The analysis was carried out using Leica LAS AF software using 
standardized settings and exposure times. 
 
 
NP-mediated IP 
 
 
HCT116 cells were seeded into P90 plates and treated with 0.5 mg/mL of nude, DR5-NPs or 
human IgG-NPs for 2 h, the supernatant was removed and the cells washed once in PBS. The 
cells were lysed at 4 °C for 15 min in IP lysis buffer (150 mM NaCl, 20 mM Tris-HCl, 
pH7.4, containing 0.2% NP-40, 10% glycerol) and centrifuged for 10 min at 4 °C at 20 000 g 
to precipitate NPs with the attached proteins. The supernatant was collected and the 
remaining precipitate washed once in lysis buffer and separated by centrifugation before 
denaturation. 40% of the precipitated protein and 2% of the supernatant were subject to 
Western blot analysis using anti-caspase 8 (1:5000, Enzo Life Sciences, UK) and anti-DR5 
antibody (1:1000, Cell Signaling Technologies, Danvers, MA). 
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Assessment of apoptotic cell death 
 
 
Cells were seeded in P90, 6, 12 or 96 well plates. Cell viability was assessed by MTT reagent 
(Sigma-Aldrich, UK) and data presented relative to PBS-treated cells. Caspase activity was 
analyzed in cell lysates (5 µg of protein) by Caspase-Glo® 3/7 or 8 assays (Promega, UK) and 
the data expressed as fold change to control cells. Cell cycle progression was analyzed by PI 
staining and flow cytometry after cell fixation and RNase A (Qiagen, UK) digestion. 
Expression of phosphatidyl serine was analyzed by annexin V-FITC/PI staining following 
Logue et al. 49. RhTRAIL was obtained from Merck Millipore, UK, birinapant from 
TetraLogic Pharmaceutical (Malvern, PA). Silencing of XIAP and DR5 was carried out using 
validated siRNA and assessed by Western blot and flow cytometry respectively as previously 
described 21, 50. For the assessment of clonogenic survival, 400 cells were seeded into 6 well 
plates and treated for 1 h upon adherence, the medium replaced and incubated for 12 d to 
allow the formation of colonies (stained with 0.4% crystal violet solution). Cell lysates were 
prepared with RIPA lysis buffer supplemented with protease inhibitors. Protein expression 
levels were assessed by Western immunoblot incubating the membrane with primary 
antibodies overnight at 4 °C (BAX, XIAP, pThr68-Chk2, 1:1000, Cell Signaling 
Technologies, Danvers, MA; BAK, 1:1000, Santa Cruz Biotechnology, Germany; FLIP, 
1:1000, Enzo Life Sciences, UK; α-tubulin as loading control, 1:10000, Abcam, UK; PARP, 
1:5000, eBioscience, UK) and secondary antibodies for 1 h at room temperature.  
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HCT116 xenograft study 
 
 
All in vivo experiments were carried out in accordance with the UK Home Office and 
approved by Queen’s University Belfast Ethical Review Committee. 2 x 106 HCT116 cells 
were implanted subcutaneously onto both flanks of 9 weeks old female Balb/c nude mice 
(Harlan Laboratories, UK) using matrigel (BD, UK). The animals were treated intravenously 
via tail vein injections with 2 mg of NPs or controls (corresponding to 1.9 mg/kg CPT and 
1.7 mg/kg conatumumab) when xenografts reached an average size of 60 mm3. Tumor tissue 
was lysed with RIPA lysis buffer containing protease and phosphatase inhibitors using the 
TissueLyser LT (Qiagen, UK) and subject to Western blotting. The intensity of protein bands 
was determined by densitometry using Image Lab™ Software (BioRad, UK). Formalin-fixed 
tumors were paraffin-embedded, sectioned (6 µm) and stained with anti-cleaved caspase 3 
antibody (1:200, Signaling Technologies, Danvers, MA) according to the manufacturer’s 
recommendation. Images were taken using an Olympus BH2 microscope at x10 
magnification. 
 
 
Statistical analysis 
 
 
One-way ANOVA with Tukey’s post-hoc test or the Student’s t-test was used to analyze 
statistical significance between several groups or two groups respectively. The Kruskal 
Wallis-test was applied to determine the statistical significance of tumor volume in vivo. The 
 22 
null hypothesis was accepted for p ≥0.05 or labeled with * for p < 0.05, ** for p < 0.01 and 
*** for p < 0.001 when rejected. 
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Tables 
 
 
Table 1. Characterization of NPs with/without CPT loading before/after surface modification 
with DR5-specific antibody. 
 
 
Blank nude 
NP 
Blank DR5-
NP 
CPT nude 
NP CPT DR5-NP 
Diameter [nm] a 178  ± 8 217 ± 29 208  ± 8 223  ± 10 
Polydispersity index a 0.05 ± 0.02 0.13 ± 0.03 0.15  ± 0.02 0.20  ± 0.04 
Zeta potential [mV] a - 4.0 ± 1.0 - 2.2 ± 0.8 - 2.2 ± 0.3 - 2.0 ± 0.6 
High content CPT NP  
µg/mg polymer 
(% Entrapment 
efficiency) 
N/A N/A 
18 ± 3  
(54 ± 9) 
Low content CPT NP 
µg/mg polymer 
(% Entrapment 
efficiency) 
N/A N/A 
3.4 ± 0.6 
(68 ± 12) 
a measured in PBS         mean±SD (n=4-6) 
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Figure legends 
 
 
Figure 1. Preparation and characterization of DR5-targeted and CPT-loaded PEGylated 
PLGA NPs. (a) Schematic overview of the preparation process of CPT DR5-NPs. (b) 
Relative phagocytosis of fluorescent DR5-targeted PLGA and PEG-PLGA NPs after 
incubation with murine Raw 264.7 cells for 1 h, mean±SD (n=3). (c) SEM images of blank 
and high content CPT DR5-NPs. (d) Cumulative release of CPT from high content NPs using 
dialysis against 50% serum in PBS at 37 °C, mean±SD (n=4). 
 
 
Figure 2. DR5-NPs initiate extrinsic apoptosis in HCT116 colorectal cancer cells. (a) 
Confocal microscopy images of cells treated with nude or DR5-NPs (0.2 mg/mL) for 1 h; cell 
nucleus in blue, NPs in red and DR5 in green; the white arrows highlight co-localization in 
yellow. (b) Western blot analysis of DR5 and caspase 8 in the precipitate and supernatant 
following treatment of live cells for 2 h and subsequent NP-mediated immunoprecipitation 
(IP). (c) Caspase 8 and 3/7 activity following treatment with DR5-NPs (0.2 mg/mL) or 
appropriate controls for 6 h, mean±SD (n=3). (d) Dose-response curves of DR5-NPs and free 
anti-DR5 antibody (ab) after 48 h of incubation, mean±SEM, n=3 (free) and 4 (DR5-NPs). 
(e) Reduction of colony formation following treatment with DR5-NPs (0.1 mg/mL) or 
controls for 1 h and subsequent incubation for 12 d. (f) Western blot analysis of humanized 
DR5-specific antibody remaining on the NP surface following incubation in 50% serum at 37 
°C for the indicated time. (g) Caspase 8 activity in HCT116 cells following treatment with 
DR5-NPs (0.2 mg/ml) for 6 h after pre-incubation in 50% serum at 37 °C for the indicated 
time, mean±SD (n=3). 
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Figure 3. CPT loading enhances apoptosis induced by DR5-NPs in colorectal cancer cells. 
(a) Cell cycle analysis in HCT116 cells using RNase A/PI staining and flow cytometry 
following NP treatment (0.05 mg/mL) for 24 h. (b) Western blot analysis of phosphorylated 
Chk2 (pThr68-Chk2) following treatment of HCT116 cells with NPs (0.02 mg/mL) for 24 h. 
(c) Annexin V/PI staining after treatment of HCT116 cells with 0.10 or 0.05 mg/mL NPs and 
appropriate controls for 24 or 48 h respectively, n=3; live: double negative; early apoptotic: 
annexin V positive; necrotic: PI positive; late apoptotic: double positive. (d) Dose-response 
curves of LoVo, HT29 and RKO colorectal cancer cell lines after treatment with NPs for 24 
h, mean±SD, (n=3). 
 
 
Figure 4. DR5-targeting potentiates the anti-tumor effects of CPT in HCT116 xenografts. (a) 
Tumor volume in Balb/c nude mice, dashed lines indicate the time points of treatment with 
PBS, NP formulations or free anti-DR5 antibody (1.7 mg/kg DR5-specific antibody, 1.9 
mg/kg CPT), mean±SEM, (n=8-10). (b) Body weight, mean±SEM (n=4-5). (c) Images of 
paraffin-embedded tumor tissue excised on day 23 and stained for cleaved caspase 3, x10 
magnification. (d) Western blot analysis of pThr68-Chk2 in lysates of individual tumors 
excised on day 23; corresponding densitometry shown in the right panel, mean±SD (n=4-5). 
 
 
Figure 5. DR5-NPs overcome BAX deficiency in HCT116 cells in combination with CPT. 
(a) Western blot analysis of PARP, XIAP and BAX in wild-type (WT) and BAX-/- HCT116 
cells following pre-treatment with CPT (Pre CPT, 0.1 µM) for 16 h and subsequent treatment 
with DR5-NPs (0.05 mg/mL) for 6 h. (b) Quantification of apoptotic (sub-G1) cell 
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populations analyzed by RNase A/PI staining and flow cytometry following treatment with 
birinapant (1 µM) for 1 h and subsequent treatment with DR5-NPs (0.05 mg/mL) for 6 h; 
mean±SD (n=3). (c) RNase A/PI staining and flow cytometry analysis of BAX-/- HCT116 
cells following serial NP treatment (0.01 mg/mL) as outlined in the flow chart; quantification 
of the sub-G1 cell populations in the right panel, mean±SD (n=4). (d) Caspase 8 and 3/7 
activity following the treatment regime; mean±SD (n=3). (e) Western blot analysis of PARP, 
XIAP, DR5 and BAK in BAX-/- HCT116 cells following the treatment regime. 
 
 
Figure 6. DR5-NPs overcome high FLIP levels in HCT116 cells with enhanced effects in 
combination with CPT. (a) Western blot analysis of PARP and FLIPL following treatment 
with free CPT for 24 h. (b) Caspase 8 activation following treatment with free CPT for 24 h, 
mean±SD (n=3). (c) Western blot analysis of PARP and FLIP in FLIPL, FLIPS and empty 
vector (EV) transduced HCT116 cells following treatment with free CPT (1 µM) for 24 h. (d) 
Annexin V binding in FLIPL, FLIPS and EV transduced cells following treatment with NPs 
(0.05 mg/mL) for 12 h, mean±SD (n=3). (e) Western blot analysis of PARP and FLIP in 
FLIPS and EV transduced cells following treatment with NPs (0.05 mg/mL) for 12 h.  
  
